|[August 27, 2014]
MVI Vaccine to Be Used in Clinical Trial of a New Combination Approach to Immunotherapy Funded by the Prostate Cancer Foundation and the Movember Foundation
MADISON, Wis. --(Business Wire)--
Madison Vaccines Incorporated (MVI), a clinical stage biopharmaceutical
company, today said its lead product candidate MVI-816 (pTVG-HP) will be
used in a clinical trial testing a two-pronged immunotherapy approach to
treat metastatic prostate cancer. The vaccine is intended to stimulate
the immune system to fight the cancer cells while a PD-1 pathway
inhibitor is designed to prevent the cancer cells from camouflaging
themselves to expose the cancer cells to attack. The trial will be
conducted with a $1.5 million 2014 Movember-Prostate Cancer Foundation
(PCF) Challenge Award funded by the Movember Foundation and supported by
the Movember-PCF Challenge Award program. The research will be conducted
under the direction of Douglas McNeel, M.D., Ph.D., Professor of
Medicine at the University of Wisconsin-Madison.
"This is important validation for our young company, to have our lead
vaccine selected as part of a competitive grant by the leading
philanthropic organization funding and accelerating prostate cancer
research globally," said Richard Lesniewski, Ph.D., President of MVI.
"This trial supplements MVI's current clinical strategies, and may
advance the timetable for demonstrating clinical efficacy of our lead
MVI-816 targets prostatic acid phosphatase (PAP), a well-defined
prostate antigen, and is currently in development to delay the onset of
metastatic disease after primary therapy. It is a plasmid DNA vaccine
that can be delivered to patients by simple intradermal injection, is
readily manufactured in cost-effective manner, and is highly stable.
"This award represents a 1.5 million dollar commitment to the potential
of immunotherapy," said Dr. McNeel. "While PD-1 inhibitors have worked
well in certain cancers, they have not been as successful in treating
metastatic prostate cancer. We believe this two-pronged immune
activation approach, pairing a PD-1 pathway inhibitor with a vaccine,
will generate the results we need to have a significant impact on this
Jonathan W. Simons, M.D., President and CEO, Prostate Cancer Foundation,
said, "Our Foundation has opened doors for a whole new generation of
cancer vaccines such as Dr. McNeel's new biotechnology. Our partnership
with Movember has been pivotal in making new cancer vaccine research
Mark Hedstrom, US Country Director for Movember, added, "Together with
PCF, the Movember Foundation is committed to having an everlasting
impact on the face of men's health, and with projects like this, working
towards a world where no man will die from prostate cancer."
Discussions are underway to determine which PD-1 pathway inhibitor will
be used in the trial. Patient enrollment is expected to begin within the
next year. Separately, a company-sponsored Phase 2 clinical trial of
MVI-816 in early stage prostate cancer is currently underway.
For more information about the Prostate Cancer Foundation, go to www.pcf.org.
For more information about the Movember Foundation, go to www.movember.com.
Wisconsin-based MVI is developing two plasmid DNA vaccines to treat men
with prostate cancer. MVI-816 (pTVG-HP) is designed to activate
patients' immune systems to kill prostate cancer cells after initial
treatment but before incurable metastases to the bone. MVI-118 (pTVG-AR)
is a second DNA vaccine being developed that targets the human androgen
receptor, the critical biological target that in many cases is
responsible for resistance to current therapies. MVI has licensed
patented technologies that were developed in the laboratory of Dr.
Douglas McNeel at the University of Wisconsin-Madison. More information
is available at www.madisonvaccines.com.
[ InfoTech Spotlight's Homepage ]